Optimapharm is a mid-sized, full-service CRO operating globally with the slogan "We Deliver on Your Promises." The company's main focus is on delivering new therapies to enhance and save patients' lives, with a strong emphasis on prioritizing its people and exceeding client expectations. With 26 strategically located offices across Europe, Optimapharm provides unparalleled access to patients and investigators worldwide. Key company figures include a 510+ staff member team, an investigator network of 1000+ active sites, and a high client retention rate of 85%. The company boasts of a highly educated workforce with a low staff turnover rate of less than 15% across the organization, offering cost-effective solutions at a regional level. Optimapharm's services are structured around Regulatory Affairs, Medical Affairs, Medical Writing, Clinical Monitoring, Project Management, Data Management, Biostatistics, Safety and Vigilance, Quality, and Translation Services. The company adopts a flexible and collaborative approach to optimize design, planning, and project delivery. It has established a strong track record of delivery excellence and features committed and stable project teams, leading to a high level of repeat business over the years. Founded in 2005, Optimapharm operates in numerous countries including Austria, Belgium, Czech Republic, France, Germany, Greece, Romania, Sweden, Switzerland, the United Kingdom, and the United States of America. The company offers Full-service study delivery, Stand-alone service, and Functional Service Provider to best respond to planned clinical development and resource clinical projects efficiently. Overall, Optimapharm's extensive industry expertise, commitment to delivery excellence, and strong client relationships position it as a leading player in the global CRO market.
There is no investment information
No recent news or press coverage available for Optimapharm.